5 news items
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ALNY
7 Apr 24
.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
ALNY
5 Mar 24
.
About RNAi
RNAi (RNA interference) is a natural cellular
- Prev
- 1
- Next